Why Choose Neuland Labs as Your Global CDMO Partner

An ideal contract development and manufacturing organization (CDMO) partner offers deep expertise, impeccable compliance, and a collaborative approach from development through commercialization.

Neuland Laboratories meets these criteria as a global CDMO specializing in small-molecule Active Pharmaceutical Ingredients (APIs) and peptide therapeutics.

With four decades of experience, Neuland provides the technical strengths and reliability that pharmaceutical and biotechnology innovators demand.

Expertise in Small Molecule APIs and Complex Peptides

Neuland Labs brings proven expertise in both classical small-molecule chemistry and cutting-edge peptide synthesis.

Established in 1984, this global CDMO has over 40 years of API development and manufacturing experience. The company has successfully developed dozens of novel APIs (including highly specialized compounds like deuterated drugs) for clinical trials and commercial use. On the peptide front, Neuland is one of the few CDMOs adept in all major peptide production methodologies – solid-phase, solution-phase, and hybrid synthesis.

In fact, Neuland has demonstrated its peptide prowess by producing 35 kg of a complex decapeptide (10-amino-acid) under cGMP for a U.S. biotech, enabling that program to advance through Phase 3 clinical trials. Such achievements underscore a track record of tackling challenging chemistries and scales that other manufacturers might struggle with.

Not only does Neuland excel in peptides, but its repertoire of advanced organic chemistry is equally noteworthy, for example, stereoselective syntheses of chiral molecules, cyanation and halogenation reactions, and even handling PEGylated and cyclic peptide conjugates. 

Strong Regulatory Track Record and Quality Compliance

Neuland Labs distinguishes itself with an outstanding compliance history across major global regulatory agencies. The company operates three manufacturing facilities that are all U.S. FDA-inspected and cGMP compliant.

In fact, this global CDMO has successfully cleared 17 U.S. FDA inspections to date, often with zero critical observations – an impressive indicator of its quality systems and culture of compliance. Moreover, Neuland’s facilities have been audited and approved by other stringent regulators: they were among the first Indian API sites audited by the China FDA (CFDA), received approval from Japan’s PMDA as far back as 2009, and have undergone certification audits by the European Directorate for the Quality of Medicines (EDQM) to supply APIs to the EU.

This global regulatory footprint gives clients confidence that Neuland can navigate the required filings (IND, NDA, DMFs) and meet the compliance standards in any target market.

Large-Scale Manufacturing Capacity for Commercial Supply

The company’s three manufacturing sites house a combined reactor volume of 941,000 liters – a massive capacity that is on par with global leaders in API production. This includes a range of reactor sizes and technologies, enabling efficient scale-up and tech transfer from pilot to plant.

For example, Neuland can seamlessly progress from a few milliliters of laboratory reactors to several liters of production reactors when moving from Phase I trials to Phase III and commercial batches. The multi-purpose plants are designed to handle complex chemistries, including potent or hazardous reactions, while maintaining strict GMP standards for both clinical and commercial supply.

What does this mean for your company? Simply put, this global CDMO has the headroom to support your product’s growth at every stage. Early on, you might need only a few kilos of API – easily handled in Neuland’s kilo labs and pilot plants. But if the drug is successful, demand can quickly turn into tens of metric tons per year.

Neuland’s capacity ensures they can scale to that large-volume manufacturing without bottlenecks. In one case, Neuland dedicated 150,000+ liters of reactor volume to produce about 50 metric tons per annum of a commercial API for a client, and even invested in further expansion to double that output when the client’s forecast grew. 

Advanced R&D Capabilities Driving Innovation

A true development partner brings brainpower and innovation to solve complex process challenges. Neuland Labs boasts a state-of-the-art R&D center with over 360 scientists in chemistry and analytics. 

From the outset of a project, Neuland’s scientists focus on designing efficient, scalable synthetic routes and identifying the best molecule form through crystallization, polymorph, and salt screening studies.

They apply Quality by Design (QbD) principles and perform Design of Experiments (DoE) to optimize reaction parameters, improve yields, and enhance purity profiles. Difficult reactions are systematically de-risked in this global CDMO’s process engineering lab, which features tools like reaction calorimetry and parallel reactors to study kinetics and safety, ensuring that processes are robust and safe before scaling up.

Project Execution Excellence with Digital Project Management

From day one, Neuland conducts a thorough project kick-off and risk assessment with a cross-functional team, then integrates all tasks into a detailed project plan.

Using its digitized system, the global CDMO provides partners with transparency into task-level progress, next steps, and any issues in real time. Stakeholders, including the client, can access dynamic dashboards that show current project status, upcoming milestones, and any risks or deviations being tracked.

This level of visibility is coupled with proactive management. For instance, the system’s real-time reporting generates early warning signals if a delay or problem is looming, allowing the team to initiate corrective actions promptly. Regular governance meetings with senior management add another layer of oversight to ensure critical projects get the needed attention.

Sustainability, Green Chemistry, and EHS Excellence

The global CDMO has embraced green chemistry principles and rigorous Environment, Health, and Safety (EHS) standards across its operations. All three manufacturing units and the R&D center are ISO 14001 (environmental management) and ISO 45001 (occupational safety) certified, reflecting global best practices in EHS.

Neuland has implemented advanced pollution control and waste management systems. For example, its sites use zero liquid discharge effluent treatment plants that thoroughly treat and recycle wastewater, ensuring no harmful discharge into the environment. Similarly, air emissions are tightly controlled with high-efficiency scrubbers and filters to keep all pollutants well within prescribed limits. 

Neuland has achieved a Five-Star Safety Rating (the highest grade) for two of its major production units, a testament to strong safety performance and continuous improvement. The workforce at Neuland is extensively trained in safety protocols, and the company reports 100% compliance with all legal and customer safety audits. 

In recognition of its sustainability initiatives, Neuland Labs was honored as one of the top six Indian companies in the pharma/biotech sector for sustainability, featured in the S&P Sustainability Yearbook 2024. This external acknowledgement highlights Neuland’s leadership in ESG (Environmental, Social, and Governance) performance among its peers.

A Global CDMO That Delivers

Neuland Labs rises to the top of the list by combining scientific prowess, operational excellence, and integrity. Its demonstrated expertise in small molecule and peptide development, unblemished regulatory track record, huge manufacturing capacity, and innovative R&D approach address every facet a sponsor could ask for in a global CDMO partner. 

With Neuland as your CDMO, you gain a trusted ally to accelerate development, navigate regulatory hurdles, and scale up confidently for commercial success.

FAQs

1. How does Neuland Labs support tech transfer from other CDMOs or in-house R&D?

A- Global CDMO Neuland Labs follows a structured tech transfer protocol with deep process evaluation, gap assessment, and risk mitigation, ensuring a smooth scale-up without compromising quality, timelines, or regulatory readiness.

2. How does Neuland Labs ensure consistency in raw material sourcing?

A- Neuland emphasizes supply chain control, including in-house synthesis of key starting materials, dual sourcing strategies, and vendor qualification systems to ensure consistent quality, availability, and traceability of raw materials.

3. What kind of digital tools does Neuland use to enhance collaboration with clients?

A- Global CDMO Neuland offers clients access to a secure digital platform with real-time dashboards, document sharing, and milestone tracking, enabling proactive collaboration and transparency throughout the development lifecycle.

4. Does Neuland Labs offer early-phase development or only commercial manufacturing?

A- Global CDMO Neuland supports the full lifecycle—from preclinical and Phase I development to commercial supply—helping clients de-risk programs early while ensuring seamless transition to scale when needed.